CRVO Relative Valuation - Diffusion Pharmaceuticals Inc - Alpha Spread
D

Diffusion Pharmaceuticals Inc
NASDAQ:CRVO

Watchlist Manager
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Watchlist
Price: 17.47 USD 10.57% Market Closed
Market Cap: 144.2m USD
Have any thoughts about
Diffusion Pharmaceuticals Inc?
Write Note

Relative Value

The Relative Value of one CRVO stock under the Base Case scenario is 8.96 USD. Compared to the current market price of 17.47 USD, Diffusion Pharmaceuticals Inc is Overvalued by 49%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CRVO Relative Value
Base Case
8.96 USD
Overvaluation 49%
Relative Value
Price
D
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
14
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.7
Forward
13.7
vs History
vs Industry
Median 3Y
-7.6
Median 5Y
-21.6
Industry
23.9
Forward
-10.5
vs History
vs Industry
Median 3Y
-8.8
Median 5Y
-23.3
Industry
22.2
vs History
vs Industry
Median 3Y
-8.8
Median 5Y
-23.3
Industry
24
vs History
26
vs Industry
Median 3Y
5
Median 5Y
8.7
Industry
2.5
vs History
12
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.4
Forward
13
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.5
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-14.1
Industry
5.1
Forward
-9.1
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-14.1
Industry
4.7
Forward
-9.7
vs History
vs Industry
Median 3Y
-7.6
Median 5Y
-20.5
Industry
6.6
vs History
vs Industry
Median 3Y
-7.6
Median 5Y
-20.5
Industry
4.7
vs History
17
vs Industry
Median 3Y
-48.8
Median 5Y
39.2
Industry
4.7

Multiples Across Competitors

CRVO Competitors Multiples
Diffusion Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
144.2m USD 14.9 -28.6 -12.7 -12.7
US
Abbvie Inc
NYSE:ABBV
341.9B USD 6.2 64.6 15.8 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
127.8B USD 9.5 29.6 25.9 28.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.3B USD 11.9 -251.7 26.8 28.1
US
Gilead Sciences Inc
NASDAQ:GILD
104.5B USD 3.8 99.3 9.4 12
US
Epizyme Inc
F:EPE
94.1B EUR 1 981.8 -505.7 -550.7 -536
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.7 22.4 27.9
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.5 -63 -56.9
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.4B USD 15.1 -485.3 213.7 328.9
P/E Multiple
Earnings Growth
US
D
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Average P/E: 57.5
Negative Multiple: -28.6
N/A
US
Abbvie Inc
NYSE:ABBV
64.6
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.6
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -251.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
36.7
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -485.3 N/A
EV/EBITDA Multiple
EBITDA Growth
US
D
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Average EV/EBITDA: 47.7
Negative Multiple: -12.7
N/A
US
Abbvie Inc
NYSE:ABBV
15.8
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.9
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -550.7 N/A
AU
CSL Ltd
ASX:CSL
22.4
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -63 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
213.7
N/A
EV/EBIT Multiple
EBIT Growth
US
D
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Average EV/EBIT: 69.5
Negative Multiple: -12.7
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.6
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
28.7
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
38%
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -536 N/A
AU
CSL Ltd
ASX:CSL
27.9
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
328.9
N/A

See Also

Discover More
Back to Top